ћедико-биологический
информационный портал
дл€ специалистов
 
Ѕ»ќћ≈ƒ»÷»Ќ— »… ∆”–ЌјЋ Medline.ru

—ќƒ≈–∆јЌ»≈ ∆”–ЌјЋј:
‘изико-химическа€ биологи€

 линическа€ медицина

ѕрофилактическа€ медицина

ћедико-биологические науки


ј–’»¬:

‘ундаментальные исследовани€

ќрганизаци€ здравохраниени€

»стори€ медицины и биологии



ѕоследние публикации

ѕоиск публикаций

Articles

јрхив :  2000 г.  2001 г.  2002 г. 
               2003 г.  2004 г.  2005 г. 
               2006 г.  2007 г.  2008 г. 
               2009 г.  2010 г.  2011 г. 
               2012 г.  2013 г.  2014 г. 
               2015 г.  2016 г.  2017 г. 
               2018 г.  2019 г.  2020 г. 

–едакционна€ информаци€:
        ќпубликовать статью
        Ќаша статистика


 –≈ƒј ÷»я:
√лавный редактор

«аместители главного редактора

„лены редколлегии
—пециализированные редколлегии


 ”„–≈ƒ»“≈Ћ»:
‘едеральное государственное бюджетное учреждение науки
"»нститут токсикологии ‘едерального медико-биологического агентства"
(‘√Ѕ”Ќ »“ ‘ћЅј –оссии)

»нститут теоретической и экспериментальной биофизики –оссийской академии наук.

ќќќ "»÷  ќћ ќЌ".




јдрес редакции и реквизиты

199406, —анкт-ѕетербург, ул.√аванска€, д. 49, корп.2

ISSN 1999-6314

–оссийска€ поискова€ система
»скать: 


«
Vol. 14, Art. 68 (pp. 861-879)    |    2013       
»

Antiphospholipid syndrome
Koloskov A.V., 1,2,3 Philippova O.I., 1,2 Stolitsa A.A., 3 Bessmeltsev S.S. 4

SBIHE ЂNord-Western State Medical University named after I.I. Mechnicovї under the Ministry of Public Health and Social Affairs of Russian Federation, St.Petersburg, Russia
2 City Hospital є 26, St.Petersburg, Russia
3 FSBI ЂAlmazov federal heart, blood and endocrinology centerї
Federal specialized perinatal center, St.Petersburg, Russia
4 FSBI ЂRussian Research Institute of Hematology and Transfusiology of FMBA Russiaї, St.Petersburg, Russia



Brief summary

Antiphospholipid syndrome is a systemic autoimmune disease associated with thrombosis and/or recurrent fetal loss in the setting of detectable antiphospholipid antibodies. The major antigenic target has been identifed as β2-glycoprotein I, which mediates binding of antiphospholipid antibodies to target cells including endothelial cells, monocytes, platelets and trophoblasts, leading to prothrombotic and proinfammatory changes that ultimately result in thrombosis and/or fetal loss. Since the establishment of the international preliminary classification and diagnostic criteria for antiphospholipid syndrome in 1999 was a considerable amount of work in the field of basic research, which provided new information. Clinical criteria of antiphospholipid syndrome were revised in Sydney in 2006. The mere presence of antiphospholipid antibodies does not mean the development of antiphospholipid syndrome in a patient. For the diagnosis of antiphospholipid syndrome requires the combination of at least one and one clinical laboratory test. Sydney criteria do not recommend using the term "secondary antiphospholipid syndrome." The studies failed to find differences in the clinical effects of the action of antiphospholipid antibodies in patients with primary and secondary antiphospholipid syndrome.


Key words

antiphospholipid syndrome, β2-glycoprotein I, clinical criteria





(The article in PDF format. For preview need Adobe Acrobat Reader)



Open article in new window

Reference list

1. Harris E. Syndrome of the black swan // Br. J. Rheumatol. Ц 1987. Ц V. 26. Ц P. 324Ц326.


2. Wilson W., Gharavi A., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome // Arthritis Rheumotol. Ц 1999. Ц V.42. - P. 1309Ц1311.


3. Miyakis S., Lockshin M., Atusmi T. et al. International consensus statement on an update of the classification criteria for defnite antiphospholipid syndrome (APS) // J. Thromb. Haemost. -2006. Ц V. 4. Ц P. 295Ц306.


4. Fleck R., Rapaport S., Rao L. Anti-prothrombin antibodies and the lupus anticoagulant // Blood. Ц 1988. Ц V. 72. Ц V. 512Ц519.


5. McNeil H., Simpson R., Chesterman C., Krilis S. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H) // Proc. Natl. Acad. Sci. USA. Ц 1990. Ц V. 87. Ц P. 4120Ц4124.


6. Danowski A., Kickler T., Petri M. Anti-β2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus // J. Rheumatol. Ц 2006. Ц V. 33. Ц P. 1775Ц1779.


7. Lin W.S., Chen P.C., Yang C.D. et al // Some antiphospholipid antibodies recognize conformational epitopes shared by β2-glycoprotein I and the homologous catalytic domains of several serine proteases // Arthritis. Rheum. Ц 2007. Ц V. 56. Ц P. 1638Ц1647.


8. Harper B.E., Wills R., Pierangeli S.S. Pathophysiological mechanisms in antiphospholipid syndrome // Int. J. Clin. Rheumtol. Ц 2011. Ц V. 6. Ц P. 157Ц171.


9. Ruffatti A., Del Ross T., Ciprian M. et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study // Ann. Rheum. Dis. Ц 2009. Ц V. 68. Ц P. 397Ц399.


10. Danowski A., de Azevedo M., de Souza Papi J., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus // J. Rheumtol. Ц 2009. Ц V. 36. Ц P. 1195Ц1199.


11. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature // Blood. Ц 2003. Ц V. 101. Ц P. 1827Ц1832.


12. de Groot P., Lutters B., Derksen R. et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis // J. Thromb. Haemost. Ц 2005. Ц V. 3. Ц P. 1993Ц1997.


13. 12. Cervera R., Khamashta M., Shoenfeld Y. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients // Ann. Rheum. Dis. Ц 2009. Ц V. 68. Ц P. 1428Ц1432.


14. Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients // Arthritis Rheumotol. Ц 2006. Ц V. 54. Ц P. 2568Ц2576.


15. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // J. Thromb. Haemost. Ц 2006. Ц V. 4. Ц P. 295Ц306.


16. 13 Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome // N. Engl. J. Med. Ц 2002. Ц V. 346. Ц P. 752Ц763.


17. Vianna J.L., Khamashta M.A., Ordi-Ros J. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients // Am. J. Med. Ц 1994. Ц V. 96. Ц P. 3Ц9.


18. Salmon J.E., Girardi G., Holers V.M. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis // Ann. Rheum. Dis. Ц 2002. Ц V. 61. Ц P. ii46Ц50.


19. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation // Nat. Med. Ц 2004.- V. 10. Ц P. 1222Ц1226.


20. Giannakopoulos B., Krilis S. A. The pathogenesis of antiphospholipid syndrome // N. E. J. Med. Ц 2013. Ц V. 368. Ц P. 1033Ц1044.


21. Evain-Brion D., Guibourdenche J., Tsatsaris V., Fournier T. Human trophoblast differentiation // Bull. Acad. Nat. Med. Ц 2009. Ц V. 193. Ц P. 1017Ц1025.


22. Mahler M., Norman G. L., Meroni P. L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome // Autoimm. Rev. Ц 2012. Ц V. 12. Ц P. 313Ц317.


23. de Groot P. G., Urbanus R. T. The significance of autoantibodies against 𝛽2-glycoprotein I // Blood. Ц 2012. Ц V. 120. Ц P. 266Ц274.


24. de Laat B., Pengo V., Pabinger I. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study // J. Thromb. Haemost. Ц 2009. Ц V. 7. Ц P. 1767Ц1773.


25. Marchetti T., Cohen M., de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications // Clin. Develop. Immun. Volume 2013, Article ID 159124, http://dx.doi.org/10.1155/2013/159124


26. van Horn J.T., Craven C., Ward K. et al. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipis-like syndromes // Placenta. Ц 2004. Ц V. 25. Ц P. 642Ц648.


27. Skrzypczak J., Jasinski P., Wirstlein P. et al. Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia // Ginekol. Polska. Ц 2011. Ц V. 82. Ц P. 652Ц663.


28. Shamonki J.M., Salmon J.E., Hyjek E., Baergen R.N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies // Am. J. Obst. Gyn. Ц 2007. Ц V. 196. Ц P. 167.e1Ц167.e5.


29. Cavazzana I., Manuela N., Irene C. et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? // J. Autoimm. Ц 2007. Ц V. 28. Ц P. 160Ц164.


30. Gerosa M., de Angelis V., Tresoidi L. et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women // Ann. Rheum. Dis. Ц 2009. Ц V. 68. - article 210.


31. Cohen D., Buurma A., Goemaere N.N. et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss // J. Pathol. Ц 2011. Ц V. 225. Ц P. 502Ц511.


32. Girardi G., Berman J., Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome // J. Clin. Invest. Ц 2003. Ц V. 112. Ц P. 1644Ц1654.


33. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity // Immunity. Ц 2011. Ц V. 34. Ц P. 637Ц650.


34. Satta N., Kruithof E.K.O., Reber G., de Moerloose P. Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides // Molec. Immun. Ц 2008. Ц V. 46. Ц P. 145Ц157.


35. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B. et al. NF𝜅B is an essential intermediate in the activation of endothelial cells by anti-𝛽2-glycoprotein 1 antibodies // Thromb. Haemost. Ц 2002. Ц V. Ц 88. Ц P. 851Ц857.


36. E. Raschi, C. Testoni, D. Bosisio et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies // Blood. Ц 2003. Ц V. 101. Ц P. 3495Ц 3500.


37. Vega-Ostertag M., Casper K., Swerlick R. et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies // Arthritis Rheum. Ц 2005. Ц V. 52. Ц P. 1545Ц1554.


38. Satta N., Dunoyer-Geindre S., Reber G. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies // Blood. Ц 2007. Ц V. 109. Ц P. 1507Ц1514.


39. Satta N., Kruithof E.K.O., Fickentscher C. et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies // Blood. Ц 2001. Ц V. 117. Ц P. 5523Ц5531.


40. Poulton K., Rahman A., Giles I. Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review // Sem. Arthritis Rheum. Ц 2012. Ц V. 41. Ц P. 720Ц736.


41. Prinz N., Clemens N., Strand D. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells // Blood. Ц 2011. Ц V. 118. Ц P. 2322Ц2332.


42. Mulla M.J., Brosens J.J., Chamley L.W. et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway // Am. J. Reprod. Imm. Ц 2009. Ц V. 62. Ц P. 96Ц111.


43. Meroni P.L., Gerosa M., Raschi E. et al. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss // Clin. Rev. Allerg. Imm. Ц 2008. Ц V. 34. Ц P. 332Ц337.


44. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheum. Ц 2011. Ц V. 7. Ц P. 330Ц339.


45. Meroni P.L., Tedesco F., Locati M. et al. Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view // Lupus. Ц 2010. Ц V. 19. Ц P. 453Ц456.


46. Mulla M.J., Myrtolli K., Brosens J.J. et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity // Am. J. Reprod. Immun. Ц 2010. Ц V. 63. Ц P. 339Ц348.


47. Jovanovic M., Bozic M., Kovacevic T. et al. Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo) // Acta Histochem. Ц 2010. Ц V. 112. Ц P. 34Ц41.


48. Adler R.R., Ng A.K., Rote N. S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR // Biol. Reprod. Ц 1995. Ц V. 53. Ц P. 905Ц910.


49. Di Simone N., Raschi E., Testoni C. et al. Pathogenic role of anti-𝛽2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of 𝛽2-glycoprotein I binding to trophoblast cells and functional effects of anti-𝛽2- glycoprotein I antibodies in vitro // Ann. Rheum. Dis. Ц 2005. Ц V. 64. Ц P. 462Ц467.


50. Francis J., Rai R., Sebire N. J. et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome // Molec. Hum. Reprod. Ц 2006. Ц V. 12. Ц P. 435Ц442.


51. Gris J.C., Bouvier S., Molinari N. et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational Study // Blood. Ц 2012. Ц V. 119. Ц P. 2624Ц2632.


52. Cervera R., Piette J., Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients // Arthritis Rheum. Ц 2002. Ц V. 46. Ц P. 1019Ц1027.


53. Costedoat-Chalumeau N., Guettrot-Imbert G., Leguern V. et al. Pregnancy and antiphospholipid syndrome // Rev. Med. Inter. Ц 2012. Ц V. 33. Ц P. 209Ц216.


54. Nodler J., Moolamalla S. R., Ledger E. M. et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset // BMC Pregn. Child. Ц 2009. Ц V. 9. - article 11.


55. Rai R. S., Regan L., Clifford K. et al. Antiphospholipid antibodies and 𝛽2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach // Hum. Reprod. Ц 1995. Ц V. 10. Ц P. 2001Ц2005.


56. Mekinian A., Lachassine E., Nicaise-Roland P. et al. European registry of babies born to mothers with antiphospholipid syndrome // Ann. Rheum. Dis. Ц 2013. Ц V. 72. Ц P. 217Ц222.


57. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention, УPrevalence of Autism


spectrum disordersЧAutism and developmental disabilities monitoring network, 14 Sites, United States, 2008 // Morb. Mort. Week. Rep. Ц 2012. Ц V. 61. Ц P. 1Ц19.



—видетельство о регистрации сетевого электронного научного издани€ N 077 от 29.11.2006
∆урнал основан 16 но€бр€ 2000г.
¬ыдано ћинистерством –‘ по делам печати, телерадиовещани€ и средств массовых коммуникаций
(c) ѕерепечатка материалов сайта Medline.Ru возможна только с письменного разрешени€ редакции

–азмещение рекламы

Rambler's Top100